ImmunityBio (IBRX) Assets Average (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Assets Average data on file, last reported at $574.3 million in Q1 2026.

• Assets Average for Q1 2026 came in at $574.3 million, up 67.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $574.3 million (up 67.26% YoY), and the FY2025 annual result was $442.4 million, changed 0.29% from the prior year.
• Assets Average improved to $574.3 million in Q1 2026 per IBRX's latest filing, from $510.4 million in the prior quarter.
• Over five years, Assets Average peaked at $574.3 million in Q1 2026 and troughed at $317.3 million in Q2 2023.
• A 5-year average of $404.2 million and a median of $373.8 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average jumped 99.28% in 2022, then retreated 24.13% in 2025.
• A 5-year view of Assets Average shows it stood at $357.6 million in 2022, then surged by 30.98% to $468.4 million in 2023, then fell by 20.21% to $373.8 million in 2024, then surged by 36.57% to $510.4 million in 2025, then climbed by 12.5% to $574.3 million in 2026.
• Business Quant data shows IBRX's Assets Average at $574.3 million in Q1 2026, $510.4 million in Q4 2025, and $460.5 million in Q3 2025.